Hematologic and cytogenetic response to lenalidomide monotherapy in acute myeloid leukemia arising from JAK2 V617F positive, del(5)(q13q33) myelodysplastic syndrome Lenalidomide (Revlimid; Celgene Co.) has ameliorated cytopenias and induced cytogenetic responses in patients with myelodysplastic syndrome (MDS), especially those with del(5)(q13q33). 1 Additionally, we have similarly reported cytogenetic and hematologic response in a patient with myelofibrosis with myeloid metaplasia with del(5)(q13q33) whom also had the JAK2 V617F . 2 However, no data exist regarding the efficacy of lenalidomide in patients with del(5)(q13q33) who have progressed to acute myeloid leukemia (AML). An 82-year-old woman presented to our institution with a several year history of untreated MDS associated with mild anemia, thrombocytosis and isolated del(5)(q13q33). Subsequently, in response to worsening cytopenias (hemoglobin 9.9 g/dl, leukocytes 1.5 Â 10 9 /l (neutrophils 0.45 Â 10 9 /l)), and peripheral circulating blasts (2%), a bone marrow was obtained. The marrow demonstrated minimally differentiated AML (AML-M0) Figure 1 Effects of lenalidomide monotherapy on an 82-year-old woman with a MDS with both the JAK2 V617F mutation and the del(5)(q13q33). (a) Bone marrow aspirate (hematoxylin and eosin; Â 1000 oil lens -light microscopy) at the time of diagnosis of leukemic transformation with 34% myeloblasts. (b) Repeat bone marrow aspirate (same conditions) after 3 months of lenalidomide with 5% myeloblasts, improved granulocytic maturation and normal peripheral blood counts.
Letters to the Editor with 34% blasts and trilineage dysplasia (Figure 1a) . Karyotypic analysis showed 11 of 20 metaphases containing the del(5)(q13q33), whereas allele-specific PCR demonstrated the presence of JAK2 V617F . After discussion of the therapeutic alternatives with the patient (including the likelihood of failure with induction chemotherapy with secondary AML (median survival 3-4 weeks 3 with standard therapy in age 480 years), and the responses reported with lenalidomide for patients with interstitial chromosome 5q deletions and MDS, 1 she elected to begin lenalidomide at a dose of 10 mg/day. She tolerated the agent well, without any adverse effects. After 3 months of treatment, she had normal peripheral blood counts, and no evidence of circulating blasts. A repeat marrow exam showed a slightly hypercellular marrow, with significant improvement in granulocytic maturation and with a significant decrease in the myeloblasts to 5% blasts (Figure 1b) . Additionally, the karyotypic abnormalities had completely resolved to show a normal female karyotype. This would be considered a partial response by the International Working Group for Acute Myeloid Leukemia, 4 nearly a complete response had the blast percentage been o5%. After 2 additional months of lenalidomide (still at 10 mg/day) the patient had evidence of disease progression, with recurrent leukopenia, thrombocytopenia and 10% blasts in the marrow. Additionally, repeat karyotypic analysis showed clonal progression, with 10/30 metaphases having the del(5)(q13q33), and 7 of them with multiple other structural abnormalities including loss of 17p. Alternative therapy was initiated.
To our knowledge, this is the first report of lenalidomide monotherapy resulting in achieveving a solid 5-month partial remission in an elderly patient with high-risk AML. The patient reported a high quality of life during this time, and was free of transfusions, hospitalization and infection. The coexistence of the JAK2 V617F mutation, a finding more commonly associated with myeloproliferative disorders, is an additional intriguing aspect to this case. JAK2 V167F has been described in 6.2% MDS patients with del(5)(q13q33), 5 and the clinical significance is unknown. Few agents offer any legitimate therapeutic benefit to elderly patients with secondary AML. Lenalidomide may have activity as monotherapy against AML arising from del(5q)-associated chronic myeloid disorders. However, the apparent ability of the disorders to undergo clonal evolution suggests that combination or sequential therapy of lenalidomide with other novel or traditional agents should be explored. 
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